Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » First-Quarter Sales by Product Line

This excerpt taken from the EYE 8-K filed Apr 25, 2007.

First-Quarter Sales by Product Line

Below are sales highlights of first-quarter 2007 results. Growth rates reflect comparisons to the same period in 2006 and include the impacts of foreign currency. For more information, see the table entitled “Global Sales” that accompanies this release.

Cataract/Implant sales rose 6.1 percent to $127.7 million.

 

  •  

Total intraocular lens (IOL) sales rose 13.6 percent to $75.9 million.

 

 

•

  

Monofocal IOL sales rose 11.5 percent to $63.0 million, reflecting continued strong growth of the Tecnis® IOL franchise.

 

 

•

  

Refractive IOL sales rose 25.3 percent to $12.9 million, reflecting demand for the company’s ReZoom®, Tecnis® Multifocal, VerisyseTM and VeriflexTM IOLs.

 

  •  

Viscoelastic sales declined 4.9 percent to $27.5 million, due primarily to competitive and reimbursement pricing pressure in certain international markets.

 

 

•

  

Phacoemulsification sales declined 5.4 percent to $20.3 million, due primarily to lower equipment sales ahead of the planned introduction of the new WhiteStar SignatureTM

 

2

 

phacoemulsification system during the American Society of Cataract and Refractive Surgery annual meeting later this month. Sales were partially offset by 6.4 percent growth in surgical pack sales.

Laser Vision Correction (LVC) sales rose 6.0 percent to $64.6 million.

 

  •  

Procedures and related sales rose 12.4 percent to $45.6 million.

 

  •  

U.S. procedure volumes grew 3.4 percent and U.S. custom procedure mix reached 60.8 percent for the trailing 12 months ended March 30, 2007.

 

  •  

International procedure sales grew 83.3 percent to $4.6 million.

 

 

•

  

System sales declined 6.0 percent to $10.4 million, due primarily to the rollout of Iris Registration technology in the year-ago quarter and partially offset by $1.3 million in sales of WaveFront SciencesTM products.

Eye Care sales rose 4.4 percent to $59.3 million.

 

  •  

Multipurpose sales rose 4.7 percent to $33.9 million.

 

 

•

  

U.S. COMPLETE® MoisturePlus™ solution sales rose 23.1 percent to $12.6 million, reflecting favorable market share growth trends.

 

  •  

Eye care sales declined 29.3 percent and 15.1 percent in Asia Pacific and Japan, respectively, reflecting the impacts of the voluntary recall and temporary shutdown of the company’s manufacturing plant in China in late 2006.

 

  •  

Hydrogen peroxide sales declined 2.6 percent to $13.8 million, reflecting the continued contraction of this market in Japan and Europe.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki